FYI Paper that may be of interest to some of you published in the latest edition of the Journal of European Public Policy
BW
David McDaid
LSE Health and Social Care
G Permanand, E Mossialos
DOI: 10.1080/13501760500160607
JOURNAL OF EUROPEAN PUBLIC POLICY 12 (4): 687-709 AUG 2005
Abstract: This paper offers a theoretical perspective on pharmaceutical policy-making in the European Union, and shows the lack of a single European market in medicines to be the result of a clash between the supranational free movement rules and national healthcare policy competencies. The paper considers the roles of the European Commission, the member states, the industry and consumer interests (patients) as the main stakeholders, and frames the discussion within an integrated macro- and meso-level approach. Here we draw on Wilson's `politics of (regulatory) politics' typology, tying it to Scharpf's `constitutional asymmetry' perspective on EU policy. This enables the development of a broad sphere of analysis, allowing us to make observations on the EU regulatory arrangement for medicines as a whole. Specifically, the paper shows the extent to which industrial rather than health(care) policy interests have driven the development of regulatory policy in the sector, and seeks to understand the political dynamics shaping the on-going evolution of the regulatory framework.
Author Keywords: constitutional asymmetry; European Union; pharmaceuticals; policy-making; regulation; single market
Addresses: Permanand G (reprint author), Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, Houghton St, London, WC2A 2AE England
Univ London London Sch Econ & Polit Sci, LSE Hlth & Social Care, London, WC2A 2AE England
London Sch Econ, Dept Social Policy, London, England
|